{"analyses":[{"ciLowerLimit":"0.87","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.28","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","paramType":"Hazard Ratio (HR)","paramValue":"1.05"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"86.2"},{"groupId":"OG001","value":"87.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"2884"},{"groupId":"OG001","value":"2877"}],"units":"Participants"}],"description":"Compare time to distant recurrence-free survival (DRFS). Distant recurrence is defined according to STEEP criteria as the time from randomization to the date of the first event: distant recurrence or death from any cause. Patients with a locoregional recurrence will continue to be followed for DRFS. Surviving patients who are event-free will be censored at: the date of last disease assessment, or withdrawal of consent to be followed, or death whichever came first. Direct comparison between arms used time to DRFS events and Kaplan-Meier Log-rank analysis. Due to the medians not yet achieved, the percentage of patients considered DRFS at 4 years is reported.","groups":[{"description":"Palbociclib at a dose of 125 mg orally once daily, Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle for a total duration of 2 years, in addition to standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG000","title":"Palbociclib Plus Endocrine Therapy (Arm A)"},{"description":"Standard adjuvant endocrine therapy for a duration of at least 5 years.","id":"OG001","title":"Endocrine Therapy Alone (Arm B)"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"4 years","title":"Distant Recurrence-free Survival (DRFS)","type":"SECONDARY","unitOfMeasure":"percentage of patients"}